This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

50/100

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Background Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau 181 , total-Tau, Aβ42 and Aβ40) in cerebrospinal fluid (CSF) of patients with DLB and AD, focusing especially on the prodromal stage. Methods A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Bousiges, O., Bombois, S., Schraen, S., Wallon, D., Quillard, M. M., Gabelle, A., et al. (2018). Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage. Journal of neurology, neurosurgery, and psychiatry. https://doi.org/10.1136/jnnp-2017-316385

Vancouver

Bousiges O, Bombois S, Schraen S, Wallon D, Quillard MM, Gabelle A, et al. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage. Journal of neurology, neurosurgery, and psychiatry. 2018. doi:10.1136/jnnp-2017-316385. PMID: 29321140.

BibTeX

@article{bousiges2018-29321140,
  author  = {Bousiges, O. and Bombois, S. and Schraen, S. and Wallon, D. and Quillard, M. M. and Gabelle, A. and Lehmann, S. and Paquet, C. and others},
  title   = {{Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage}},
  journal = {Journal of neurology, neurosurgery, and psychiatry},
  year    = {2018},
  doi     = {10.1136/jnnp-2017-316385},
  pmid    = {29321140},
  url     = {https://doi.org/10.1136/jnnp-2017-316385}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

We compared AD biomarkers (phospho-Tau 181 , total-Tau, Aβ42 and Aβ40) in cerebrospinal fluid (CSF) of patients with DLB and AD, focusing especially on the prodromal stage.
Methods A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively.
Samples were obtained from patients with prodromal DLB (pro-DLB; n=57), DLB dementia (DLB-d; n=154), prodromal AD (pro-AD; n=132) and AD dementia (n=783), and control subjects (CS; n=95).
These centres use the same diagnostic procedure and criteria to evaluate the patients.

Why it matters

This retrospective study of 1221 cerebrospinal fluid samples compared Alzheimer biomarkers in patients with dementia with Lewy bodies and Alzheimer's disease, focusing on the prodromal stage. It is a diagnostic study and does not test any treatment, cure or prevention.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants57
Evidence strengthLow

How this study scored 50/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of neurology, neurosurgery, and psychiatry)
Journal's citation record	3 / 4	Journal of Neurology Neurosurgery & Psychiatry: journal h-index 336 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	2 / 5	2018 — within 10 year(s) of the newest study here
Sample size	1 / 4	57 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	4 / 7	Cited 43 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	4.3 citations a year over 10 year(s) since 2018
Impact for its field and year	3 / 6	Cited 3.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 6 other studies in this library
Still being cited	1 / 4	Cited 11 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Frédéric Blanc: h-index 52 (OpenAlex, whole career)
Institution's track record	3 / 3	Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex)
Multi-centre collaboration	3 / 3	OpenAlex lists 22 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 29321140)
Free to read	0 / 2	Behind a paywall — scores zero
Total	50 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

Later studies that cite this one

6 studies in the alzhub library list this one in their references.

Related studies in Tau biomarkers

Also tagged “cerebrospinal”

822 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 822 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →